Curated News
By: NewsRamp Editorial Staff
August 13, 2026
Nutriband CEO to Present at 2026 Georgia Life Sciences Summit
TLDR
- Nutriband's CEO presents at the 2026 Georgia Life Sciences Summit, potentially boosting investor interest and market position.
- Nutriband's AVERSA technology integrates aversive agents into transdermal patches to deter abuse, misuse, and diversion of addictive drugs.
- Nutriband's AVERSA technology aims to prevent drug abuse and accidental exposure, contributing to safer communities and improved public health.
- Nutriband's CEO will speak at the 2026 Georgia Life Sciences Summit, highlighting innovations in abuse-deterrent patch technology.
Impact - Why it Matters
This news matters because it underscores the ongoing efforts to combat opioid abuse and diversion through innovative pharmaceutical technologies. Nutriband's AVERSA™ technology has the potential to significantly reduce the misuse of prescription drugs, which is a critical public health issue. By presenting at a major industry summit, the company is positioning itself at the forefront of abuse-deterrent formulations, which could lead to safer pain management options and potentially influence regulatory standards and investor interest in the sector.
Summary
Nutriband (NASDAQ: NTRB), a company focused on developing transdermal pharmaceutical products, announced that its CEO and Co-Founder, Gareth Sheridan, will present at the 2026 Georgia Life Sciences Summit as part of the CEO Spotlight event. The summit, scheduled for August 25-26 at the Sandy Springs Performing Arts Centre in Georgia, will bring together leaders from biotechnology, medical technology, research, manufacturing, and investment sectors. Nutriband is known for its AVERSA™ technology, an abuse-deterrent transdermal delivery system designed to incorporate aversive agents into patches to prevent abuse, diversion, misuse, and accidental exposure of drugs with abuse potential.
The company's lead product is an abuse-deterrent fentanyl patch that utilizes AVERSA™. This innovative technology can be integrated into any transdermal patch to enhance safety. The announcement was made via a press release distributed by MissionIR, a specialized communications platform that assists investor relations firms with syndicated content to increase visibility for companies within the investment community. MissionIR is part of the Dynamic Brand Portfolio under IBN, which offers services like press release distribution, editorial syndication to over 5,000 outlets, social media distribution, and corporate communications solutions.
Interested parties can view the full press release at https://ibn.fm/Un3ax, and the latest news about NTRB is available at https://ibn.fm/NTRB. Nutriband's website is www.nutriband.com. The company's participation in the summit highlights its commitment to advancing pharmaceutical safety and addressing the opioid crisis through innovative technology.
Source Statement
This curated news summary relied on content distributed by InvestorBrandNetwork (IBN). Read the original source here, Nutriband CEO to Present at 2026 Georgia Life Sciences Summit
